ACRO | 如何為抗體-藥物結合物選擇合適的靶標

ACRO | 如何為抗體-藥物結合物選擇合適的靶標

2020.11.18

You don’t want to miss this!

 

How to Pick the Suitable Target for Antibody-Drug Conjugates

ADCs (Antibody-drug conjugates) are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens with highly potent anti-cancer agents linked via a chemical linker, while sparing normal cells from damage, potentially minimizing the side effects associated with cancer therapy. Since the approval of the first ADCs in 2000, there are now nine different approved ADCs on the market and over 100 ADCs in the drug-development pipeline.

List of ADCs have been approved

We believe that with the development hotspot of ADCs from hematomas to solid tumors, choosing the suitable drug target proteins will become more and more important.

ACROBiosystems has developed a series of products with different species and tags for a variety of hot targets, which are suitable for immune, antibody screening, SPR, cell activity detection and other experiments. ACROBiosystems is committed to assisting you in drug development, and all SPR&BLI protocols are available for free. In addition, over expressed cell lines and kit products will be coming soon.

Hot Products

ACROBiosystems is continuously developing more high-quality targeting proteins of ADCs. If you have any suggestions or customized requirements, please contact us.

Product Features

>>> High purity verified by MALS

Fig1.The purity of Human Her2, His Tag (Cat. No. HE2-H5225) was more than 90% and the molecular weight of this protein is around 80-95 kDa verified by SEC-MALS.

Fig 2.The purity of Human EGF R, His Tag(Cat. No. EGR-H5222) was more than 90% and the molecular weight of this protein is around 90-115 kDa verified by SEC-MALS.

>>> High affinity validated by SPR&BLI

·    SPR

Fig 3.Herceptin (Trastuzumab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human Her2, His Tag (Cat. No. HE2-H5225) with an affinity constant of 1.07 nM as determined in a SPR assay.

Fig4.Erbitux (Cetuximab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human EGF R, His Tag (Cat. No. EGR-H5222) with an affinity constant of 1.3 nM as determined in a SPR assay.

·    BLI